Project Details
Projekt Print View

Discovery and characterisation of novel ribosome-targeting antibiotics

Subject Area Structural Biology
Biochemistry
Term from 2018 to 2022
Project identifier Deutsche Forschungsgemeinschaft (DFG) - Project number 379357354
 
Final Report Year 2022

Final Report Abstract

The translational machinery is a major target within the cell for antibiotics. The increase in multidrug resistant pathogenic bacteria is making our current arsenal of antibiotics obsolete, highlighting the urgency for the discovery and development of new antibiotics. This DFG-RSF project aimed to discover new compounds that target the ribosome and inhibit translation as well as characterize already known but poorly studied compounds. Together with our collaborators, we report the discovery and characterization of two novel translation inhibitors, tetracenomycin X and auraplanin. Both have novel binding sites on the ribosome and do not appear to exhibit crossresistance with other known clinically-used antibiotics. Moreover, both compounds have novel scaffolds and utilize previously unreported modes of interaction with the ribosome. In addition, we have characterized a variety of other translation inhibitors, including apidaecin, Bac5, mxyovalargin A and B, argyrin B, amino-negamycin, evernimicin-rosamicin and Paenilamicin B2. We believe that by understanding the structural details of the interaction of drugs with the ribosome and the mechanism by which these compounds inhibit translation, we will open new pathways for the development of improved antibiotics to overcome multi-drug resistant pathogenic bacteria.

Publications

 
 

Additional Information

Textvergrößerung und Kontrastanpassung